Literature DB >> 12798618

BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?

May-Lill Garly1, Cesário Lourenco Martins, Carlitos Balé, Mamadu Aliu Baldé, Kathryn Louise Hedegaard, Per Gustafson, Ida M Lisse, Hilton C Whittle, Peter Aaby.   

Abstract

Previous studies have suggested that the bacille Calmette-Guérin (BCG) vaccine may have a non-specific beneficial effect on childhood survival in areas with high mortality. We examined whether BCG-vaccinated children with a BCG scar or a positive tuberculin reaction had better survival than children without such reactions. As part of an ongoing two-dose measles vaccine trial for which children were recruited at 6 months of age, we examined 1813 children for BCG scar at 6 months of age and 813 BCG-vaccinated children were skin-tested for delayed hypersensitivity to tuberculin, tetanus and diphtheria. We found that BCG-vaccinated children with a BCG scar had significantly lower mortality compared with BCG scar-negative children, the mortality ratio in the first 12 months of follow-up being 0.41 (0.25-0.67). BCG-vaccinated children with a positive tuberculin test had a mortality ratio of 0.45 (0.24-0.85) compared with tuberculin negative children. These results were unchanged by control for potential confounders or using different cut-off points for a tuberculin-positive response. Exclusion of dead children who had HIV antibodies did not modify the estimate (mortality rate (MR)=0.46 (0.23-0.94)). After censoring for tuberculosis (TB) exposure at home, the mortality ratios for having a scar and being tuberculin-positive were 0.46 (0.27-0.79) or 0.42 (0.21-0.84), respectively. Children positive to tetanus or diphtheria in the skin test had the same mortality as children not responding to these vaccine-related antigens. Thus, BCG scar and a positive tuberculin reaction were associated with better survival in early childhood in an area with high mortality. Since nothing similar was found for responders to diphtheria-tetanus-pertussis (DTP) vaccine, and the effect could not be explained by protection against tuberculosis, the effect of BCG vaccination could be due to non-specific immune-stimulation protecting against other infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798618     DOI: 10.1016/s0264-410x(03)00181-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  101 in total

1.  Mycobacterium-induced potentiation of type 1 immune responses and protection against malaria are host specific.

Authors:  Kathleen R Page; Anne E Jedlicka; Benjamin Fakheri; Gregory S Noland; Anup K Kesavan; Alan L Scott; Nirbhay Kumar; Yukari C Manabe
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  BCG and Kawasaki disease in Mexico and Japan.

Authors:  Luisa Berenise Gamez-Gonzalez; Hiromichi Hamada; Beatriz Adriana Llamas-Guillen; Miguel Ruiz-Fernandez; Marco Yamazaki-Nakashimada
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

3.  Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.

Authors:  Johanneke Kleinnijenhuis; Jessica Quintin; Frank Preijers; Leo A B Joosten; Daniela C Ifrim; Sadia Saeed; Cor Jacobs; Joke van Loenhout; Dirk de Jong; Hendrik G Stunnenberg; Ramnik J Xavier; Jos W M van der Meer; Reinout van Crevel; Mihai G Netea
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

4.  Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges.

Authors:  Peter Aaby; Tobias R Kollmann; Christine Stabell Benn
Journal:  Nat Immunol       Date:  2014-10       Impact factor: 25.606

5.  Responders and non-responders to influenza vaccination: A DNA methylation approach on blood cells.

Authors:  Noémie Gensous; Claudio Franceschi; Bonnie B Blomberg; Chiara Pirazzini; Francesco Ravaioli; Davide Gentilini; Anna Maria Di Blasio; Paolo Garagnani; Daniela Frasca; Maria Giulia Bacalini
Journal:  Exp Gerontol       Date:  2018-01-31       Impact factor: 4.032

6.  Evolution of the Bacillus Calmette-Guerin Scar and Its Association with Birth and Pregnancy Characteristics in a Prospective Cohort of Infants in Iquitos, Peru.

Authors:  Francesca Schiaffino; Gwenyth O Lee; Maribel Paredes-Olortegui; Lilia Cabrera; Pablo Penataro-Yori; Robert H Gilman; Margaret N Kosek
Journal:  Am J Perinatol       Date:  2018-12-24       Impact factor: 1.862

7.  BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers.

Authors:  Magali Noval Rivas; Joseph E Ebinger; Min Wu; Nancy Sun; Jonathan Braun; Kimia Sobhani; Jennifer E Van Eyk; Susan Cheng; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

8.  Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes.

Authors:  Jessica Quintin; Sadia Saeed; Joost H A Martens; Evangelos J Giamarellos-Bourboulis; Daniela C Ifrim; Colin Logie; Liesbeth Jacobs; Trees Jansen; Bart-Jan Kullberg; Cisca Wijmenga; Leo A B Joosten; Ramnik J Xavier; Jos W M van der Meer; Hendrik G Stunnenberg; Mihai G Netea
Journal:  Cell Host Microbe       Date:  2012-08-16       Impact factor: 21.023

9.  A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses.

Authors:  Yenny Djuardi; Erliyani Sartono; Heri Wibowo; Taniawati Supali; Maria Yazdanbakhsh
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

10.  Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau.

Authors:  Adam Edvin Roth; Christine Stabell Benn; Henrik Ravn; Amabelia Rodrigues; Ida Maria Lisse; Maria Yazdanbakhsh; Hilton Whittle; Peter Aaby
Journal:  BMJ       Date:  2010-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.